Home > Haematology > Ultra-early tranexamic acid of no benefit for subarachnoid hemorrhage

Ultra-early tranexamic acid of no benefit for subarachnoid hemorrhage

Journal
The Lancet
Reuters Health- 15/01/2021 - In patients with subarachnoid hemorrhage due to a ruptured aneurysm, ultra-early, short-term tranexamic acid (TXA) did not improve clinical outcomes in a multicenter, randomized controlled trial. "The use of TXA in patients who have endured a subarachnoid hemorrhage has been a matter of debate for decades," Dr. Rene Post of the University of Amsterdam told Reuters Health by email, "We could now convincingly demonstrate that TXA does not improve the clinical outcomes in these patients at six months' follow-up." "What surprised us," he said, "was that we did not find a significant reduction in the occurrence of rebleedings between the treatment groups, whereas this was always said to be the main reason for its use." "Our study showed that in half of the patients the aneurysm was secured within 14 hours," he noted. "This early aneurysm treatment shortens the time window in which a rebleeding can occur, and thus the time window in whi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on